Women's Cancer News
Sep. 24, 2014

Maintenance pazopanib in ovarian cancer: No survival benefit
Cancer Network (Free login required)
Maintenance therapy with the oral agent pazopanib improved progression free survival by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical Oncology. More

2015 SGO International Scholar Travel Grants deadline Oct. 25
SGO
SGO is offering three International Scholar Travel Grants to assist multidisciplinary early career professionals involved in the prevention, research, treatment or care of gynecologic cancers. Scholarship applications are being accepted now through Oct. 25. The scholarship provides up to $3,300 USD for travel and lodging expenses to attend the SGO Annual Meeting on Women's Cancer® in Chicago, Illinois, March 28-31, 2015.More

Endpoints for studies of ovarian cancer
MedPage Today
The time-tested approach of a phase III clinical trial comparing drug A versus drug B has become largely infeasible relative to the myriad of legitimate options based on rapid target discovery, and in the current regulatory environment such investigations are becoming prohibitively costly, time-consuming and are unable to adjust to new discoveries during the course of the trial. This dynamic has placed a premium on reassessing our clinical trials strategy and developing meaningful clinical trial endpoints.More

Gynecologists resist FDA over popular surgical tool
The Wall Street Journal (Subscription required)
Doctors nationwide are still using a gynecological tool months after the U.S. Food and Drug Administration warned that it can spread undetected cancer, demonstrating the limits of the regulator's reach into clinical practice. More

Exercise boosts tumor-fighting ability of chemotherapy, team finds
ScienceDaily
Study after study has proven it true: exercise is good for you. But new research suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy. Their work, performed in a mouse model of melanoma, found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone.More

Terminally ill, but constantly hospitalized
NPR
New York and New Jersey are home to 12 of the 25 regions where chronically-ill patients are hospitalized longest in their last six months of life in 2011. The reasons they do this are many, but most experts agree that it has less to do with the unique characteristics and desires of people in New York and New Jersey than the health care system and culture that has evolved here.More

Finding risks, not answers, in gene tests
The New York Times (Subscription required)
Cases of frightening or confusing results from genetic tests are becoming more common because of a big recent change in genetic testing for cancer risk. Competing companies have hugely expanded the array of tests they offer, in part because new technology has made it possible to sequence many genes for the same price as one or two. More

UPMC study: Adding chemotherapy to radiation treatment not effective in treating vulvar cancer
Medical News Today
The addition of chemotherapy to post-surgical radiation treatment is not effective in treating vulvar cancer, according to Magee-Womens Hospital of UPMC research presented recently in San Francisco at the 56th annual meeting of the American Society for Radiation Oncology. Led by Dr. Sushil Beriwal, associate professor with the department of radiation oncology at the University of Pittsburgh School of Medicine and radiation oncologist at Magee, this study identified patients diagnosed with vulvar cancer between 1998 and 2011 who had undergone surgery to remove the cancer and required adjuvant radiation therapy because the disease had spread to their lymph nodes. More